Emerald Clinical Trials, a worldwide leading clinical research company, announced a change of management today. Mary Gunn has resigned with immediate effect. The board has appointed Glenn Kerkhof, a long-time board member and experienced cro manager, an interim CEO.
The board of directors took the search for a new CEO and asked Glenn Kerkhof to lead the company during this time to ensure continuity, stability and strong implementation.
“We thank Mary for her contribution,” said Sean Carney, CEO. “Emerald Clinical Trials is a leading order research company with a global range. With Glenn as an interim CEO, we are confident that we can keep our dynamics and continue to offer our customers excellent performance,” said Sean Carney.
Glenn Kerkhof has more than 30 years of leadership experience in clinical research and pharmaceutical services. Glenn was previously CEO of Chiltern, where he led the company through a significant international expansion, and worked as an Executive Chairman by George Clinical (now Emerald Clinical Trials), where he helped to shape the company’s growth in Asia.
“The strengths of Emerald Clinical lie in our therapeutic focus, our scientific depth and our close customer partnerships,” said Glenn Kerkhof. “I concentrate on a smooth transition, a strong performance for customers and the support of our global teams. I am determined to build on our swing and lead with clarity and determination,” he said.
Information on Emerald Clinical Trials Emerald Clinical Trials is a leading, global organization for clinical research, which looks after over 100 biotechnology companies and six of the ten leading pharmaceutical companies. The company, headquartered in Singapore, offers its customers comprehensive services in the field of clinical studies worldwide and offers solutions for all study phases. You can find more information at www.emeraldclinical.com.
Logo – https://mma.prnewswire.com/media/2657673/5437419/George_Clinical__Emerald_Clinical_Trials__logo.jpg
View original content:https://www.prnewswire.com/news-releases/emerald-clinical-trials-bestatigt-ubergangs–und-kontinuitatsplan-fur-ceo-302518815.html
OTS original text press release with the exclusive in terms of content of the sender – www.ots.at | Prn